Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed neuroendocrine tumor (NET)~  * Carcinoid at any site, with or without carcinoid syndrome~ * Pancreatic islet cell tumor~    * Prior streptozocin-based therapy not required~ * Poorly differentiated NET of any primary site (this arm closed to accrual May 2009)~    * Progression with prior treatment with cisplatin-, or carboplatin-based chemotherapy required (unless contraindicated)~* The following tumors are not allowed:~  * Endocrine organ carcinoma~ * Adrenal gland malignancies~ * Thyroid carcinoma of any histology~ * Pheochromocytoma/paraganglioma~* Advanced disease~  * Disease not amenable to surgery, radiotherapy, or combined modality therapy with curative intent~* Radiologically or clinically confirmed progressive disease~  * At least 25% increase in radiologically or clinically measurable disease~ * At least 20% increase in the longest diameter (LD) of any previously documented lesion~ * Increase in the sum of the LD of multiple lesions in aggregate of 20%, OR appearance of new lesions OR deterioration in clinical status~* Measurable disease~  * At least 1 unidimensionally measurable lesion ≥ 20 mm by conventional radiographic techniques OR ≥ 10 mm by spiral CT scan~    * Ultrasound or positron-emission tomography alone not sufficient~ * Bone lesions, ascites, peritoneal carcinomatosis, pleural or pericardial effusion, and irradiated lesions are not considered measurable disease~* Primary tumors of the pancreas should not invade adjacent organs (e.g., stomach or duodenum)~* No history or evidence of brain or leptomeningeal disease (baseline CNS imaging required if clinical suspicion of CNS metastases)~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* ECOG 0-1~Life expectancy~* More than 12 weeks~Hematopoietic~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* No history of hemoptysis or bleeding diathesis~* No coagulopathy unrelated to therapeutic anticoagulation~* No significant bleeding events within the past 6 months unless the source of the bleeding has been resected~Hepatic~* Bilirubin \< 2 mg/dL~* ALT ≤ 2.5 times upper limit of normal (ULN) (5 times ULN if due to liver metastases)~Renal~* Creatinine ≤ 2 mg/dL~* Protein ≤ 1+ OR~* Protein \< 1 gm on 24-hour urine collection~* Urine protein:creatinine ratio \< 1.0~Cardiovascular~* History of thromboembolic condition allowed provided patient is on therapeutic anticoagulation at a stable dose for ≥ 4 weeks~  * Concurrent daily prophylactic aspirin (\< 325 mg/day) allowed~* No uncontrolled hypertension, myocardial infarction, clinically significant peripheral arterial ischemia, visceral arterial ischemia or angina within the past 6 months~* No serious cardiac arrhythmia requiring medication~* No cerebrovascular event (e.g., stroke or transient ischemic attack) within the past 12 months~* No history of peripheral vascular disease ≥ grade 2~* No history New York Heart Association class II-IV congestive heart failure~* Blood pressure ≤ 160/90 mm Hg~Gastrointestinal~* No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months~* No predisposing uncontrolled small bowel or colonic disorder~  * Baseline disease-related diarrhea allowed if symptoms are stable and well-characterized (i.e., # stools/day stable)~* No gastric or esophageal varices~* No gastroduodenal ulcers determined to be active by endoscopy~Pulmonary~* No interstitial pneumonia or extensive and symptomatic interstitial fibrosis~* No lung tumor in close proximity to a major vessel, or with associated cavitation~* No pleural effusion or ascites that causes ≥ grade 2 dyspnea~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for at least 3 months after completion of study treatment~* No significant traumatic injury within the past 28 days~* No currently active second malignancy other than, non-melanoma skin cancer or carcinoma in situ~  * Patients are not considered to have a currently active malignancy if they have completed therapy and are considered by their physician to be at ≤ 30% risk for relapse~* No known hypersensitivity reaction attributed to study drugs or to compounds of similar chemical or biological composition~* No symptomatic peripheral neuropathy \> grade 1~* No other severe disease or comorbidity that would preclude study participation~* No medically uncontrolled seizures~* No active infection~* No serious non-healing wound, ulcer, or bone fracture~* No psychiatric illness or social situation that would preclude study compliance~* No other severe, concurrent disease, infection, or co-morbidity that in the judgement of the investigator would constitute a hazard for study participation~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Recovered from prior cytokine therapy~* At least 4 weeks since prior immunotherapy~* No prior tyrosine kinase inhibitors or anti-vascular endothelial growth factor (VEGF) angiogenic inhibitors~Chemotherapy~* See Disease Characteristics~* At least 4 weeks since prior chemotherapy~* No prior oxaliplatin~* Prior chemoembolization therapy allowed provided it did not affect areas of measurable disease~Endocrine therapy~* Prior and concurrent somatostatin analogs allowed for symptomatic control and/or control of hormone hypersecretion only provided treatment was initiated \> 3 months prior to study entry~Radiotherapy~* See Disease Characteristics~* At least 4 weeks since prior radiotherapy and recovered~  * Prior radiotherapy must not affect areas of measurable disease~* No concurrent radiotherapy to only site of measurable disease~Surgery~* Recovered from prior surgery~* Prior cryotherapy allowed provided it did not affect areas of measurable disease~* At least 28 days since prior major surgical procedure or open biopsy~* At least 7 days since minor surgical procedure, fine-needle aspirations, or core biopsy~* No prior organ allograft~* No concurrent major surgery~Other~* At least 4 weeks since prior participation in an experimental drug study~* No other concurrent investigational agents~* No other concurrent anticancer therapy~* No halogenated antiviral agents~* Concurrent antiplatelet agents allowed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FOLFOX with Bevacizumab (Type: EXPERIMENTAL): Starting on Day 1, administered every two weeks:~5-fluorouracil: 2400 mg/ m2 CIV; over 46-48 hours Leucovorin: 200 mg/ m2; over 2 hours Oxaliplatin : 85 mg/m2; over 2 hours Bevacizumab: 5 mg/kg IV over 30-90 minutes

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues